title: Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
abstract: Parkinson's disease is caused primarily by degeneration of brain dopaminergic neurons in the substantia nigra and the consequent deficit of dopamine in the striatum. Dopamine replacement therapy with the dopamine precursor l-dopa is the mainstay of current treatment. After several years, however, the patients develop l-dopa-induced dyskinesia, or abnormal involuntary movements, thought to be due to excessive signaling via dopamine receptors. G protein-coupled receptor kinases (GRKs) control desensitization of dopamine receptors. We found that dyskinesia is attenuated by lentivirus-mediated overexpression of GRK6 in the striatum in rodent and primate models of Parkinson's disease. Conversely, reduction of GRK6 concentration by microRNA delivered with lentiviral vector exacerbated dyskinesia in parkinsonian rats. GRK6 suppressed dyskinesia in monkeys without compromising the antiparkinsonian effects of l-dopa and even prolonged the antiparkinsonian effect of a lower dose of l-dopa. Our finding that increased availability of GRK6 ameliorates dyskinesia and increases duration of the antiparkinsonian action of l-dopa suggests a promising approach for controlling both dyskinesia and motor fluctuations in Parkinson's disease.
authors.affiliation: Department of Pharmacology, Vanderbilt University, 2200 Pierce Avenue, PRB422, Nashville, TN 37232, USA.
authors.forename: Mohamed R
authors.initials: MR
authors.lastname: Ahmed
authors.forename: Amandine
authors.initials: A
authors.lastname: Berthet
authors.forename: Evgeny
authors.initials: E
authors.lastname: Bychkov
authors.forename: Gregory
authors.initials: G
authors.lastname: Porras
authors.forename: Qin
authors.initials: Q
authors.lastname: Li
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bioulac
authors.forename: Yonatan T
authors.initials: YT
authors.lastname: Carl
authors.forename: Bertrand
authors.initials: B
authors.lastname: Bloch
authors.forename: Seunghyi
authors.initials: S
authors.lastname: Kook
authors.forename: Incarnation
authors.initials: I
authors.lastname: Aubert
authors.forename: Sandra
authors.initials: S
authors.lastname: Dovero
authors.forename: Evelyne
authors.initials: E
authors.lastname: Doudnikoff
authors.forename: Vsevolod V
authors.initials: VV
authors.lastname: Gurevich
authors.forename: Eugenia V
authors.initials: EV
authors.lastname: Gurevich
authors.forename: Erwan
authors.initials: E
authors.lastname: Bezard
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D020820:Dyskinesias / Q000150:complications* / Q000517:prevention & control*; D004705:Endocytosis / Q000187:drug effects; D054768:G-Protein-Coupled Receptor Kinases / Q000235:genetics / Q000627:therapeutic use*; D055785:Gene Knockdown Techniques; D015316:Genetic Therapy; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D007980:Levodopa; D008251:Macaca; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D012399:Rotation; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000978:Antiparkinson Agents; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa; D016627:Oxidopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D054768:G-Protein-Coupled Receptor Kinases; C089176:G-protein-coupled receptor kinase 6
references.citation: Pharmacol Rev. 2002 Sep;54(3):527-59
references.pmid: 12223533
references.citation: J Neurosci. 2005 Feb 23;25(8):2157-65
references.pmid: 15728856
references.citation: J Biol Chem. 1996 Feb 16;271(7):3771-8
references.pmid: 8631993
references.citation: Neurobiol Dis. 2005 Mar;18(2):323-35
references.pmid: 15686961
references.citation: Neurobiol Aging. 2008 Mar;29(3):379-96
references.pmid: 17125886
references.citation: Am J Physiol. 1997 Sep;273(3 Pt 1):C953-61
references.pmid: 9316417
references.citation: J Neurosci. 2001 Sep 1;21(17):6853-61
references.pmid: 11517273
references.citation: Nat Med. 2003 Jun;9(6):762-7
references.pmid: 12740572
references.citation: J Neuropathol Exp Neurol. 2005 Nov;64(11):936-47
references.pmid: 16254488
references.citation: Neurobiol Dis. 2007 May;26(2):452-63
references.pmid: 17350277
references.citation: J Neurosci. 2007 Dec 26;27(52):14338-48
references.pmid: 18160641
references.citation: Neuron. 2003 Apr 24;38(2):291-303
references.pmid: 12718862
references.citation: Ann Neurol. 2008 Dec;64 Suppl 2:S56-64
references.pmid: 19127577
references.citation: J Neurochem. 2007 Aug;102(3):699-711
references.pmid: 17630981
references.citation: Science. 1998 Aug 7;281(5378):838-42
references.pmid: 9694658
references.citation: J Neurochem. 2004 Dec;91(6):1404-16
references.pmid: 15584917
references.citation: Annu Rev Physiol. 2007;69:451-82
references.pmid: 17037978
references.citation: Brain. 2001 Mar;124(Pt 3):546-57
references.pmid: 11222455
references.citation: Science. 1999 Dec 24;286(5449):2495-8
references.pmid: 10617462
references.citation: Eur J Neurosci. 1998 Aug;10(8):2694-706
references.pmid: 9767399
references.citation: Genome Biol. 2006;7(9):236
references.pmid: 17020596
references.citation: J Neurosci. 2003 Nov 12;23(32):10265-73
references.pmid: 14614085
references.citation: J Neurosci. 1992 Oct;12(10):4045-55
references.pmid: 1403099
references.citation: J Neurochem. 1999 Feb;72(2):682-92
references.pmid: 9930741
references.citation: J Comp Neurol. 1995 May 8;355(3):418-26
references.pmid: 7636023
references.citation: J Biol Chem. 2001 Oct 5;276(40):37409-14
references.pmid: 11473130
references.citation: Ann Neurol. 2005 Jan;57(1):17-26
references.pmid: 15514976
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3363-7
references.pmid: 9096399
references.citation: J Neurochem. 2008 Mar;104(6):1622-36
references.pmid: 17996024
references.citation: Eur J Neurosci. 2002 Jan;15(1):120-32
references.pmid: 11860512
references.citation: Biol Psychiatry. 2007 Apr 1;61(7):836-44
references.pmid: 16950226
references.citation: Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9
references.pmid: 15885624
references.citation: J Neurosci. 2002 Jun 15;22(12):5042-54
references.pmid: 12077200
references.citation: Annu Rev Physiol. 2007;69:483-510
references.pmid: 17305471
references.citation: Nat Rev Neurosci. 2001 Aug;2(8):577-88
references.pmid: 11484001
references.citation: J Neurosci. 2009 Apr 15;29(15):4829-35
references.pmid: 19369551
references.citation: Neuroscience. 2001;103(1):117-23
references.pmid: 11311792
references.citation: Neuron. 1999 Dec;24(4):1029-36
references.pmid: 10624964